Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-12

AUTHORS

Donald B. Bailey, Elizabeth Berry-Kravis, Anne Wheeler, Melissa Raspa, Florence Merrien, Javier Ricart, Barbara Koumaras, Gerd Rosenkranz, Mark Tomlinson, Florian von Raison, George Apostol

ABSTRACT

BACKGROUND: A phase II randomized, placebo-controlled, double-blind study and subsequent open-label extension study evaluated the efficacy, safety, and tolerability of mavoglurant (AFQ056), a selective metabotropic glutamate receptor subtype-5 antagonist, in treating behavioral symptoms in adolescent patients with fragile X syndrome (FXS). A novel method was applied to analyze changes in symptom domains in patients with FXS using the narratives associated with the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale. METHODS: In the core study, patients were randomized to receive mavoglurant (25, 50, or 100 mg BID) or placebo over 12 weeks. In the extension, patients received 100 mg BID mavoglurant (or the highest tolerated dose) for up to 32 months. Global improvement, as a measure of treatment response, was assessed using the CGI-I scale. Investigators assigning CGI-I scores of 1 (very much improved), 2 (much improved), 6 (much worse), or 7 (very much worse) were provided a standard narrative template to collect further information about the changes observed in patients. Investigator feedback was coded and clustered into categories of improvement or worsening to identify potential areas of improvement with mavoglurant. Treatment effect in each category was characterized using the Cochran-Mantel-Haenszel test. RESULTS: A total of 134 and 103 patients had reached 2 weeks or more of core and extension study treatment, respectively, by the pre-assigned cutoff date for investigator feedback. In the core study, 34 CGI-I scores of 1 or 2 were reported in 28 patients; one patient scored 6. Analysis of the CGI-I narratives did not indicate greater treatment response in patients receiving mavoglurant compared with placebo in any specific improvement domain. There were 54 CGI-I scores of 1 or 2 in 47 patients in the extension study. The most frequently reported categories of improvement were behavior and mood (79.3 and 76.6 % in core and extension studies, respectively), engagement (75.9 and 78.7 %), and communication (69.0 and 61.7 %). CONCLUSIONS: A method was established to capture and categorize FXS symptoms using CGI-I narratives. Although this method did not show benefit of drug over placebo, narratives from investigators were mostly based on parental report and thus do not represent a completely objective alternative assessment. TRIAL REGISTRATION: The studies described are registered at ClinicalTrials.gov with clinical trial identifier numbers NCT01357239 and NCT01433354. More... »

PAGES

1

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s11689-015-9134-5

DOI

http://dx.doi.org/10.1186/s11689-015-9134-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1022422422

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26855682


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "RTI International", 
          "id": "https://www.grid.ac/institutes/grid.62562.35", 
          "name": [
            "RTI International, Research Triangle Park, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bailey", 
        "givenName": "Donald B.", 
        "id": "sg:person.07477115377.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07477115377.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Rush University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.240684.c", 
          "name": [
            "Department of Pediatrics, Neurological Sciences, and Biochemistry, Rush University Medical Centre, 60612, Chicago, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berry-Kravis", 
        "givenName": "Elizabeth", 
        "id": "sg:person.01257012130.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01257012130.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "RTI International", 
          "id": "https://www.grid.ac/institutes/grid.62562.35", 
          "name": [
            "RTI International, Research Triangle Park, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wheeler", 
        "givenName": "Anne", 
        "id": "sg:person.01062777706.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062777706.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "RTI International", 
          "id": "https://www.grid.ac/institutes/grid.62562.35", 
          "name": [
            "RTI International, Research Triangle Park, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Raspa", 
        "givenName": "Melissa", 
        "id": "sg:person.0665432052.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665432052.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Neuroscience Development, Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Merrien", 
        "givenName": "Florence", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Novartis Pharma, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ricart", 
        "givenName": "Javier", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Neurodegeneration Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Koumaras", 
        "givenName": "Barbara", 
        "id": "sg:person.01061673153.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01061673153.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Neuroscience Development, Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rosenkranz", 
        "givenName": "Gerd", 
        "id": "sg:person.01146717776.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146717776.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Neuroscience Development, Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tomlinson", 
        "givenName": "Mark", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Neuroscience Development, Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "von Raison", 
        "givenName": "Florian", 
        "id": "sg:person.01240162273.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240162273.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Neuroscience Development, Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Apostol", 
        "givenName": "George", 
        "id": "sg:person.0740345341.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740345341.17"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/npp.2011.137", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000014576", 
          "https://doi.org/10.1038/npp.2011.137"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00213-010-2130-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001304317", 
          "https://doi.org/10.1007/s00213-010-2130-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/dbp.0b013e31829d1f20", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002550931"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/dbp.0b013e31829d1f20", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002550931"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0165-1781(97)00123-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006417322"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1034/j.1600-0447.107.s416.5.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011424525"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11689-011-9074-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015670523", 
          "https://doi.org/10.1007/s11689-011-9074-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1097/00125817-200105000-00010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017294641", 
          "https://doi.org/10.1097/00125817-200105000-00010"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1097/00125817-200105000-00010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017294641", 
          "https://doi.org/10.1097/00125817-200105000-00010"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1097/00125817-200105000-00010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017294641", 
          "https://doi.org/10.1097/00125817-200105000-00010"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0092-8674(03)00079-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018483620"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1744-859x-12-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019279273", 
          "https://doi.org/10.1186/1744-859x-12-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.nbd.2008.04.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019462743"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00213-011-2375-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020703347", 
          "https://doi.org/10.1007/s00213-011-2375-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/hup.966", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020993518"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.neuron.2012.03.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021686161"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10803-011-1370-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022732103", 
          "https://doi.org/10.1007/s10803-011-1370-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10803-011-1370-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022732103", 
          "https://doi.org/10.1007/s10803-011-1370-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/dbp.0b013e318287cd17", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025447701"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/dbp.0b013e318287cd17", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025447701"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-244x-7-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029566969", 
          "https://doi.org/10.1186/1471-244x-7-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ajmg.a.36232", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031661244"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0092-8674(91)90125-i", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031781612"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/scitranslmed.aab4109", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033467574"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/jmg.2008.063701", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035721973"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.122205699", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042026586"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ajmg.a.36511", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048052692"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.neuropharm.2005.06.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049084855"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.devcel.2008.04.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049646966"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.tins.2004.04.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049990931"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1017/s1041610296002645", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050189790"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1017/s1041610296002645", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050189790"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0092-8674(91)90397-h", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050395340"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00213-012-2947-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052767455", 
          "https://doi.org/10.1007/s00213-012-2947-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/hmg/1.6.397", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059643921"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/scitranslmed.3001708", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062686872"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1542/peds.2008-0317", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1067826913"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3310/hta7160", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071139732"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078171262", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080071522", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082857001", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-12", 
    "datePublishedReg": "2016-12-01", 
    "description": "BACKGROUND: A phase II randomized, placebo-controlled, double-blind study and subsequent open-label extension study evaluated the efficacy, safety, and tolerability of mavoglurant (AFQ056), a selective metabotropic glutamate receptor subtype-5 antagonist, in treating behavioral symptoms in adolescent patients with fragile X syndrome (FXS). A novel method was applied to analyze changes in symptom domains in patients with FXS using the narratives associated with the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale.\nMETHODS: In the core study, patients were randomized to receive mavoglurant (25, 50, or 100\u00a0mg BID) or placebo over 12\u00a0weeks. In the extension, patients received 100\u00a0mg BID mavoglurant (or the highest tolerated dose) for up to 32\u00a0months. Global improvement, as a measure of treatment response, was assessed using the CGI-I scale. Investigators assigning CGI-I scores of 1 (very much improved), 2 (much improved), 6 (much worse), or 7 (very much worse) were provided a standard narrative template to collect further information about the changes observed in patients. Investigator feedback was coded and clustered into categories of improvement or worsening to identify potential areas of improvement with mavoglurant. Treatment effect in each category was characterized using the Cochran-Mantel-Haenszel test.\nRESULTS: A total of 134 and 103 patients had reached 2\u00a0weeks or more of core and extension study treatment, respectively, by the pre-assigned cutoff date for investigator feedback. In the core study, 34 CGI-I scores of 1 or 2 were reported in 28 patients; one patient scored 6. Analysis of the CGI-I narratives did not indicate greater treatment response in patients receiving mavoglurant compared with placebo in any specific improvement domain. There were 54 CGI-I scores of 1 or 2 in 47 patients in the extension study. The most frequently reported categories of improvement were behavior and mood (79.3 and 76.6\u00a0% in core and extension studies, respectively), engagement (75.9 and 78.7\u00a0%), and communication (69.0 and 61.7\u00a0%).\nCONCLUSIONS: A method was established to capture and categorize FXS symptoms using CGI-I narratives. Although this method did not show benefit of drug over placebo, narratives from investigators were mostly based on parental report and thus do not represent a completely objective alternative assessment.\nTRIAL REGISTRATION: The studies described are registered at ClinicalTrials.gov with clinical trial identifier numbers NCT01357239 and NCT01433354.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s11689-015-9134-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1040543", 
        "issn": [
          "1866-1947", 
          "1866-1955"
        ], 
        "name": "Journal of Neurodevelopmental Disorders", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "name": "Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study", 
    "pagination": "1", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "6ad31c64ef2cb749ade0c778dbda1ef1905c1320e23559c7aff1196cd74d8f2d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26855682"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101483832"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s11689-015-9134-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1022422422"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s11689-015-9134-5", 
      "https://app.dimensions.ai/details/publication/pub.1022422422"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T15:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8663_00000550.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2Fs11689-015-9134-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s11689-015-9134-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s11689-015-9134-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s11689-015-9134-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s11689-015-9134-5'


 

This table displays all metadata directly associated to this object as RDF triples.

258 TRIPLES      21 PREDICATES      64 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s11689-015-9134-5 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Na51c6a3659914d8b8acd07c92246428f
4 schema:citation sg:pub.10.1007/s00213-010-2130-2
5 sg:pub.10.1007/s00213-011-2375-4
6 sg:pub.10.1007/s00213-012-2947-y
7 sg:pub.10.1007/s10803-011-1370-2
8 sg:pub.10.1007/s11689-011-9074-7
9 sg:pub.10.1038/npp.2011.137
10 sg:pub.10.1097/00125817-200105000-00010
11 sg:pub.10.1186/1471-244x-7-7
12 sg:pub.10.1186/1744-859x-12-2
13 https://app.dimensions.ai/details/publication/pub.1078171262
14 https://app.dimensions.ai/details/publication/pub.1080071522
15 https://app.dimensions.ai/details/publication/pub.1082857001
16 https://doi.org/10.1002/ajmg.a.36232
17 https://doi.org/10.1002/ajmg.a.36511
18 https://doi.org/10.1002/hup.966
19 https://doi.org/10.1016/0092-8674(91)90125-i
20 https://doi.org/10.1016/0092-8674(91)90397-h
21 https://doi.org/10.1016/j.devcel.2008.04.003
22 https://doi.org/10.1016/j.nbd.2008.04.002
23 https://doi.org/10.1016/j.neuron.2012.03.009
24 https://doi.org/10.1016/j.neuropharm.2005.06.004
25 https://doi.org/10.1016/j.tins.2004.04.009
26 https://doi.org/10.1016/s0092-8674(03)00079-5
27 https://doi.org/10.1016/s0165-1781(97)00123-6
28 https://doi.org/10.1017/s1041610296002645
29 https://doi.org/10.1034/j.1600-0447.107.s416.5.x
30 https://doi.org/10.1073/pnas.122205699
31 https://doi.org/10.1093/hmg/1.6.397
32 https://doi.org/10.1097/dbp.0b013e318287cd17
33 https://doi.org/10.1097/dbp.0b013e31829d1f20
34 https://doi.org/10.1126/scitranslmed.3001708
35 https://doi.org/10.1126/scitranslmed.aab4109
36 https://doi.org/10.1136/jmg.2008.063701
37 https://doi.org/10.1542/peds.2008-0317
38 https://doi.org/10.3310/hta7160
39 schema:datePublished 2016-12
40 schema:datePublishedReg 2016-12-01
41 schema:description BACKGROUND: A phase II randomized, placebo-controlled, double-blind study and subsequent open-label extension study evaluated the efficacy, safety, and tolerability of mavoglurant (AFQ056), a selective metabotropic glutamate receptor subtype-5 antagonist, in treating behavioral symptoms in adolescent patients with fragile X syndrome (FXS). A novel method was applied to analyze changes in symptom domains in patients with FXS using the narratives associated with the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale. METHODS: In the core study, patients were randomized to receive mavoglurant (25, 50, or 100 mg BID) or placebo over 12 weeks. In the extension, patients received 100 mg BID mavoglurant (or the highest tolerated dose) for up to 32 months. Global improvement, as a measure of treatment response, was assessed using the CGI-I scale. Investigators assigning CGI-I scores of 1 (very much improved), 2 (much improved), 6 (much worse), or 7 (very much worse) were provided a standard narrative template to collect further information about the changes observed in patients. Investigator feedback was coded and clustered into categories of improvement or worsening to identify potential areas of improvement with mavoglurant. Treatment effect in each category was characterized using the Cochran-Mantel-Haenszel test. RESULTS: A total of 134 and 103 patients had reached 2 weeks or more of core and extension study treatment, respectively, by the pre-assigned cutoff date for investigator feedback. In the core study, 34 CGI-I scores of 1 or 2 were reported in 28 patients; one patient scored 6. Analysis of the CGI-I narratives did not indicate greater treatment response in patients receiving mavoglurant compared with placebo in any specific improvement domain. There were 54 CGI-I scores of 1 or 2 in 47 patients in the extension study. The most frequently reported categories of improvement were behavior and mood (79.3 and 76.6 % in core and extension studies, respectively), engagement (75.9 and 78.7 %), and communication (69.0 and 61.7 %). CONCLUSIONS: A method was established to capture and categorize FXS symptoms using CGI-I narratives. Although this method did not show benefit of drug over placebo, narratives from investigators were mostly based on parental report and thus do not represent a completely objective alternative assessment. TRIAL REGISTRATION: The studies described are registered at ClinicalTrials.gov with clinical trial identifier numbers NCT01357239 and NCT01433354.
42 schema:genre research_article
43 schema:inLanguage en
44 schema:isAccessibleForFree true
45 schema:isPartOf Nd5c50bcbcea34e16952d236c43403a64
46 Nd921100d5ba84a6387b1fb45cd795d59
47 sg:journal.1040543
48 schema:name Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study
49 schema:pagination 1
50 schema:productId N5200fb324bbc4771b04a4990c34747ca
51 N87f0099f372640bf90c436c9901b6c85
52 N8e6e27b9082d46eb8cb607f9c37fae55
53 Nbd03df1191d343b2801c54a086044956
54 Nf147894d3e17474aaff129515e389733
55 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022422422
56 https://doi.org/10.1186/s11689-015-9134-5
57 schema:sdDatePublished 2019-04-10T15:08
58 schema:sdLicense https://scigraph.springernature.com/explorer/license/
59 schema:sdPublisher Nb594131c3307439ea57d0375f5f74667
60 schema:url http://link.springer.com/10.1186%2Fs11689-015-9134-5
61 sgo:license sg:explorer/license/
62 sgo:sdDataset articles
63 rdf:type schema:ScholarlyArticle
64 N1472cc2672df44a08d65f222237588e9 schema:affiliation N2ab2dd7f8b8a4cbb937f479a4096fd3f
65 schema:familyName Ricart
66 schema:givenName Javier
67 rdf:type schema:Person
68 N15ce788e56db45ef9fdbea469dc50a5c rdf:first N313ec69de6ce489a9ceb084042e1b378
69 rdf:rest Nef4d2270d9be46d4a34dbb74a77ad425
70 N1633235966864ed4adf6f357434e78f6 rdf:first N508cb73761df437eaeae41bf1910d5a3
71 rdf:rest Nd1912fd44255400cbb7dbed63a778349
72 N288ee3aaaf2243468e354f1d7d95b986 rdf:first sg:person.01061673153.64
73 rdf:rest N963a06915bcd41f2936716a76d312847
74 N2ab2dd7f8b8a4cbb937f479a4096fd3f schema:name Novartis Pharma, Barcelona, Spain
75 rdf:type schema:Organization
76 N313ec69de6ce489a9ceb084042e1b378 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
77 schema:familyName Merrien
78 schema:givenName Florence
79 rdf:type schema:Person
80 N508cb73761df437eaeae41bf1910d5a3 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
81 schema:familyName Tomlinson
82 schema:givenName Mark
83 rdf:type schema:Person
84 N5200fb324bbc4771b04a4990c34747ca schema:name doi
85 schema:value 10.1186/s11689-015-9134-5
86 rdf:type schema:PropertyValue
87 N725feca9000c4a429c1c757cda57fb82 rdf:first sg:person.0665432052.49
88 rdf:rest N15ce788e56db45ef9fdbea469dc50a5c
89 N87f0099f372640bf90c436c9901b6c85 schema:name pubmed_id
90 schema:value 26855682
91 rdf:type schema:PropertyValue
92 N8e6e27b9082d46eb8cb607f9c37fae55 schema:name nlm_unique_id
93 schema:value 101483832
94 rdf:type schema:PropertyValue
95 N963a06915bcd41f2936716a76d312847 rdf:first sg:person.01146717776.25
96 rdf:rest N1633235966864ed4adf6f357434e78f6
97 N970ba5ced3dc43a487d94aa77b25af7d rdf:first sg:person.01062777706.40
98 rdf:rest N725feca9000c4a429c1c757cda57fb82
99 Na51c6a3659914d8b8acd07c92246428f rdf:first sg:person.07477115377.43
100 rdf:rest Ncaf172c4c2834610891b995464c8b994
101 Nb23c2c6b8fb0452eb917a21e5de107da rdf:first sg:person.0740345341.17
102 rdf:rest rdf:nil
103 Nb594131c3307439ea57d0375f5f74667 schema:name Springer Nature - SN SciGraph project
104 rdf:type schema:Organization
105 Nbd03df1191d343b2801c54a086044956 schema:name dimensions_id
106 schema:value pub.1022422422
107 rdf:type schema:PropertyValue
108 Ncaf172c4c2834610891b995464c8b994 rdf:first sg:person.01257012130.41
109 rdf:rest N970ba5ced3dc43a487d94aa77b25af7d
110 Nd1912fd44255400cbb7dbed63a778349 rdf:first sg:person.01240162273.44
111 rdf:rest Nb23c2c6b8fb0452eb917a21e5de107da
112 Nd5c50bcbcea34e16952d236c43403a64 schema:issueNumber 1
113 rdf:type schema:PublicationIssue
114 Nd921100d5ba84a6387b1fb45cd795d59 schema:volumeNumber 8
115 rdf:type schema:PublicationVolume
116 Nef4d2270d9be46d4a34dbb74a77ad425 rdf:first N1472cc2672df44a08d65f222237588e9
117 rdf:rest N288ee3aaaf2243468e354f1d7d95b986
118 Nf147894d3e17474aaff129515e389733 schema:name readcube_id
119 schema:value 6ad31c64ef2cb749ade0c778dbda1ef1905c1320e23559c7aff1196cd74d8f2d
120 rdf:type schema:PropertyValue
121 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
122 schema:name Medical and Health Sciences
123 rdf:type schema:DefinedTerm
124 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
125 schema:name Clinical Sciences
126 rdf:type schema:DefinedTerm
127 sg:journal.1040543 schema:issn 1866-1947
128 1866-1955
129 schema:name Journal of Neurodevelopmental Disorders
130 rdf:type schema:Periodical
131 sg:person.01061673153.64 schema:affiliation https://www.grid.ac/institutes/grid.418424.f
132 schema:familyName Koumaras
133 schema:givenName Barbara
134 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01061673153.64
135 rdf:type schema:Person
136 sg:person.01062777706.40 schema:affiliation https://www.grid.ac/institutes/grid.62562.35
137 schema:familyName Wheeler
138 schema:givenName Anne
139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062777706.40
140 rdf:type schema:Person
141 sg:person.01146717776.25 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
142 schema:familyName Rosenkranz
143 schema:givenName Gerd
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146717776.25
145 rdf:type schema:Person
146 sg:person.01240162273.44 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
147 schema:familyName von Raison
148 schema:givenName Florian
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240162273.44
150 rdf:type schema:Person
151 sg:person.01257012130.41 schema:affiliation https://www.grid.ac/institutes/grid.240684.c
152 schema:familyName Berry-Kravis
153 schema:givenName Elizabeth
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01257012130.41
155 rdf:type schema:Person
156 sg:person.0665432052.49 schema:affiliation https://www.grid.ac/institutes/grid.62562.35
157 schema:familyName Raspa
158 schema:givenName Melissa
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665432052.49
160 rdf:type schema:Person
161 sg:person.0740345341.17 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
162 schema:familyName Apostol
163 schema:givenName George
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740345341.17
165 rdf:type schema:Person
166 sg:person.07477115377.43 schema:affiliation https://www.grid.ac/institutes/grid.62562.35
167 schema:familyName Bailey
168 schema:givenName Donald B.
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07477115377.43
170 rdf:type schema:Person
171 sg:pub.10.1007/s00213-010-2130-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001304317
172 https://doi.org/10.1007/s00213-010-2130-2
173 rdf:type schema:CreativeWork
174 sg:pub.10.1007/s00213-011-2375-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020703347
175 https://doi.org/10.1007/s00213-011-2375-4
176 rdf:type schema:CreativeWork
177 sg:pub.10.1007/s00213-012-2947-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1052767455
178 https://doi.org/10.1007/s00213-012-2947-y
179 rdf:type schema:CreativeWork
180 sg:pub.10.1007/s10803-011-1370-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022732103
181 https://doi.org/10.1007/s10803-011-1370-2
182 rdf:type schema:CreativeWork
183 sg:pub.10.1007/s11689-011-9074-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015670523
184 https://doi.org/10.1007/s11689-011-9074-7
185 rdf:type schema:CreativeWork
186 sg:pub.10.1038/npp.2011.137 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000014576
187 https://doi.org/10.1038/npp.2011.137
188 rdf:type schema:CreativeWork
189 sg:pub.10.1097/00125817-200105000-00010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017294641
190 https://doi.org/10.1097/00125817-200105000-00010
191 rdf:type schema:CreativeWork
192 sg:pub.10.1186/1471-244x-7-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029566969
193 https://doi.org/10.1186/1471-244x-7-7
194 rdf:type schema:CreativeWork
195 sg:pub.10.1186/1744-859x-12-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019279273
196 https://doi.org/10.1186/1744-859x-12-2
197 rdf:type schema:CreativeWork
198 https://app.dimensions.ai/details/publication/pub.1078171262 schema:CreativeWork
199 https://app.dimensions.ai/details/publication/pub.1080071522 schema:CreativeWork
200 https://app.dimensions.ai/details/publication/pub.1082857001 schema:CreativeWork
201 https://doi.org/10.1002/ajmg.a.36232 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031661244
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1002/ajmg.a.36511 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048052692
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1002/hup.966 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020993518
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1016/0092-8674(91)90125-i schema:sameAs https://app.dimensions.ai/details/publication/pub.1031781612
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1016/0092-8674(91)90397-h schema:sameAs https://app.dimensions.ai/details/publication/pub.1050395340
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1016/j.devcel.2008.04.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049646966
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1016/j.nbd.2008.04.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019462743
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1016/j.neuron.2012.03.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021686161
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1016/j.neuropharm.2005.06.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049084855
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1016/j.tins.2004.04.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049990931
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1016/s0092-8674(03)00079-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018483620
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1016/s0165-1781(97)00123-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006417322
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1017/s1041610296002645 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050189790
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1034/j.1600-0447.107.s416.5.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1011424525
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1073/pnas.122205699 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042026586
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1093/hmg/1.6.397 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059643921
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1097/dbp.0b013e318287cd17 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025447701
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1097/dbp.0b013e31829d1f20 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002550931
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1126/scitranslmed.3001708 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062686872
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1126/scitranslmed.aab4109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033467574
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1136/jmg.2008.063701 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035721973
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1542/peds.2008-0317 schema:sameAs https://app.dimensions.ai/details/publication/pub.1067826913
244 rdf:type schema:CreativeWork
245 https://doi.org/10.3310/hta7160 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071139732
246 rdf:type schema:CreativeWork
247 https://www.grid.ac/institutes/grid.240684.c schema:alternateName Rush University Medical Center
248 schema:name Department of Pediatrics, Neurological Sciences, and Biochemistry, Rush University Medical Centre, 60612, Chicago, IL, USA
249 rdf:type schema:Organization
250 https://www.grid.ac/institutes/grid.418424.f schema:alternateName Novartis (United States)
251 schema:name Neurodegeneration Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
252 rdf:type schema:Organization
253 https://www.grid.ac/institutes/grid.419481.1 schema:alternateName Novartis (Switzerland)
254 schema:name Neuroscience Development, Novartis Pharma AG, Basel, Switzerland
255 rdf:type schema:Organization
256 https://www.grid.ac/institutes/grid.62562.35 schema:alternateName RTI International
257 schema:name RTI International, Research Triangle Park, Durham, NC, USA
258 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...